ClinicalTrials.gg
RecruitingNCT07572955Updated Sep 8, 2026

A Study Of Acute Decompensated Heart Failure

An interventional study of Lung Ultrasound in Acute Decompensated Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.

Planned enrollment
2nd of 48
500 · median 36
Started
2026
with 4 others
No phase
24 of 69
6 open now
Primary completion
2028-06
later than 13 of 16 live
Registered
68th of 69
by date

Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2026, is one of 24 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 68th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Failure by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to examine shorter hospitalization length as well as a reduced rates of recurrent heart failure hospitalization compared to current standard of care in Acute Decompensated Heart Failure. A 1-day reduction in hospital length of stay in unblinded subjects receiving daily HF-FOCUS examinations compared to a blinded standard of care arm.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥18 years of age
  • Admitted to St. Mary's Hospital Cardiology Progressive Care Unit (Cardiology 1-5 teams)
  • Admission diagnosis of either:

    1. Acute systolic heart failure
    2. Acute on chronic systolic heart failure
    3. Acute diastolic heart failure
    4. Acute on chronic diastolic heart failure
    5. Acute right heart failure
    6. Acute on chronic right heart failure
    7. Failure heart biventricular
  • Able to provide and willing to undergo daily lung ultrasound examinations during their hospitalization.

Exclusion criteria

Exclusion Criteria:

  • Subjects \<18 years of age
  • Unable to provide .
  • Unwilling to undergo daily lung ultrasound examinations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    Group 1

    Patients undergoing daily lung ultrasound with the results reported to the provider care teams on admission and each morning

    Diagnostic Test: Lung Ultrasound

  • Experimental
    Group 2

    Patients undergoing daily lung ultrasound but the results will be blinded to the provider care teams

    Diagnostic Test: Lung Ultrasound

Interventions

  • Diagnostic testLung Ultrasound

    Patients will undergo lung ultrasound assessments at hospital admission, daily throughout admission, and at hospital discharge.

06

What researchers measure

Primary outcomes

  1. Number of days in the hospital

    The number of days a patient is in the hospital will be determined by the day of admission and day of discharge. The day of discharge will be defined as when the consultant physician states that the patient is medically ready for discharge from the hospital.

    Time frame: Baseline

Secondary outcomes

  1. Number of re-hospitalized patients

    Number of patients re-hospitalized will be determined by the number of patients admitted to the hospital post discharge

    Time frame: Baseline

  2. Number of deaths

    Number of deaths will be determined by number of patient deaths due to any cause

    Time frame: Baseline

  3. Change in effective diuresis

    Diuresis will be measured from a urine sample and calculated by total diuresis in liters/admission weight in kilograms

    Time frame: Baseline, up to 90 Days

  4. Change in diuretic dosing

    Diuretic dosing will be measured in mg

    Time frame: Baseline, up to 90 Days

  5. Change in Lung Congestion

    Lung congestion will be measured using a lung ultrasound and measured as a percentage

    Time frame: Baseline, up to 90 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 22 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 7, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07572955
Lead sponsor
Mayo Clinic
Responsible party
Jared G. Bird (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 7, 2026
Start date
Aug 26, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Andy Dang
Contact
dang.phong@mayo.edu
507-255-7752
Jared Bird, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion